2026-04-14T07:28:33Zhttps://recercat.cat/oai/requestoai:recercat.cat:10230/124252025-12-24T08:52:47Zcom_2072_6col_2072_452952
RECERCAT
author
López Muñoz, Laura
author
Pastor Maeso, Manuel
author
Sanz, Ferran
author
Selent, Jana
2011-07-27T08:27:56Z2011-07-27T08:27:56Z2008
Schizophrenia is a devastating mental disorder that has a large/nimpact on the quality of life for those who are afflicted and is/nvery costly for families and society.[1] Although the etiology of/nschizophrenia is still unknown and no cure has yet been/nfound, it is treatable, and pharmacological therapy often produces/nsatisfactory results. Among the various antipsychotic/ndrugs in use, clozapine is widely recognized as one ofthe/nmost clinically effective agents, even if it elicits significant side/neffects such as metabolic disorders and agranulocytosis. Clozapine/nand the closely related compound olanzapine are good/nexamples ofdrug s with a complex multi-receptor profile ;[2]/nthey have affinities toward serotonin, dopamine, a adrenergic,/nmuscarinic, and histamine receptors, among others.
© 2008 Wiley-VCH Verlag GmbH& Co. KGaA, Weinheim info:eu-repo/semantics/openAccess
Serotonina
Esquizofrènia -- Quimioteràpia
Esquizofrènia
Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta (2) adrenergic receptor template
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion